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Key Abbreviations 
MRI Magnetic resonance imaging 
PD-L1 Programmed death ligand 1 
PET Positron emission tomography 
BRAF v-Raf murine sarcoma viral oncogene 
homolog B 
WES Whole exome sequencing 
RNA-seq Ribonucleic acid sequencing 
KMT2C Lysine Methyltransferase 2C 
MLL3 Mixed lineage leukemia protein 3 
PD-1 Programmed death 1 
CD8 Cluster of differentiation 8 
ANC Absolute neutrophil count 
IgG4 Immunoglobulin G4 
CD4 Cluster of differentiation 4 
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Abstract 
An newborn female was born with a congenital pigment synthesizing melanoma of 
the scalp. Further workup revealed metastatic disease within the liver, lungs, and left 
tibia. Whole exome sequencing was performed on multiple samples which revealed 
one somatic mutation KMT2C at low allelic frequency but no B-RAF, NF-1 mutation. 
PD-L1 was moderately expressed. Treatment was initiated with the PD-1 inhibitor 
nivolumab. The patient tolerated this treatment well with minimal toxicity. She is now 
over a year out from initial diagnosis, continuing on nivolumab, with stable disease. 
 
Case 
A newborn female was noted to have a dark raised scalp lesion (Fig. 1).  The lesion 
expanded and became more raised. The patient underwent excisional biopsy. Initial 
pathology was consistent with malignant blue nevus. A second review revealed 
pigment synthesizing melanoma (Fig. 2a), 7.3mm in depth with 2 mitoses/mm2. 
There were positive margins but no ulceration or angiolymphatic invasion. Some 
areas were consistent with pre-existing sclerotic blue nevus and there were 
overlapping features with malignant blue nevus. A chest radiograph was negative 
and abdominal ultrasound demonstrated two suspicious lesions. Magnetic 
resonance imaging (MRI) revealed six hepatic lesions. She underwent biopsy of 
these and pathology was consistent with metastatic melanoma (Fig. 2b).  Brain MRI 
and bone marrow examination were negative. Whole body positron emission 
tomography (PET) imaging revealed disease in her left posterior cervical chain (SUV 
2.9) lung (SUV 2), liver (SUV 3.1), abdomen (SUV 9.24), and left tibia (SUV 10.4) 
with a pathologic fracture.  Microarray analysis from the liver lesion identified a gain 
of chromosome 6 and chromosome 9. The patient’s mother had remained healthy 
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throughout the pregnancy without any melanoma history or concerning skin lesions 
on full dermatologic examination.   
The patient was enrolled on a prospective integrative clinical sequencing trial 
(PEDS-MIONCOSEQ) and underwent paired tumor/normal whole exome 
sequencing (WES) and tumor transcriptome sequencing (RNA-Seq). Specifics of the 
sequencing procedure and bioinformatics analysis have been described previously 
1.. Only one somatic mutation, KMT2C (MLL3, p. N729D) was detected, at a low 
allele frequency (7%) in a 2nd sample while on treatment for 16 weeks. This somatic 
mutation was not seen in the original biopsy. No mutations were detected in BRAF, 
NRAS, TSC1/2 genes and no pathogenic variants were detected on germline 
sequencing. No remarkable gene copy number changes or driving fusions were 
detected. PD-L1 was moderately expressed.  
Treatment was initiated with nivolumab, a programmed cell death protein 1 (PD-1) 
inhibitor dosed at 3mg/kg every two weeks. First dose was 50%, second dose 75%, 
and subsequent dosing at 100%. With the first dose, she developed Grade II 
diarrhea2 which resolved quickly and did not recur. Following her first treatment, she 
developed a raised bony scalp lesion, concerning for progressive disease versus 
pseudo-progression. Following her third treatment, she developed left sided posterior 
cervical lymphadenopathy. With subsequent treatments, parents noted that the bony 
lesion and lymphadenopathy increased in size following treatments, and regressed 
prior to her next treatment. Reassessment of disease status was performed after six 
doses with whole body PET scan and abdominal MRI. The PET scan demonstrated 
significant lymphadenopathy, which clinically had not been present at initial PET 
scan, an increase in her pulmonary nodule, and otherwise stable disease. Abdominal 
MRI showed slight increase in hepatic lesion size. A lymph node biopsy was 
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performed following her eighth dose. Pathology revealed metastatic melanoma with 
large areas of coagulative necrosis (Fig. 2c). This could be consistent with treatment 
effect but necrosis has also been described within untreated lesions, although was 
not seen in initial pre-treatment biopsies in our patient3. 1-2% of tumor cells were 
weakly positive with PD-L1 by immunohistochemistry and a small number of CD8 
positive infiltrating lymphocytes were noted nearby (Fig. 2d). Given evidence of 
treatment effect, clinical stability, and tolerance of therapy, the decision was made to 
continue with nivolumab. Disease evaluation was performed following 14 doses with 
whole body PET and abdominal MRI. PET scan demonstrated stable number and 
size of lesions, with global decreased avidity (SUV max of 3.8). MRI of her abdomen 
showed stable number of lesions with slight decrease in size. Following her 16th 
dose, she developed grade I anemia (hemoglobin 10.2 g/dL) and grade III 
neutropenia (ANC nadir 0.8K/uL) 2. Repeat disease evaluation following 35 doses 
revealed stable disease.  
Discussion 
Childhood melanoma has been reported to account for 0.3-0.4% of all melanoma4 
and between 1-3% of pediatric malignancies. Congenital metastatic melanoma is an 
extremely rare condition that is defined as metastatic melanoma recognized at birth. 
Its incidence is difficult to determine given its rarity. Congenital melanoma is 
generally subdivided into three separate entities based on etiology:  1. Transmission 
from an affected mother by metastatic spread through the placenta. 2. Primary de 
novo cutaneous congenital melanoma arising in utero.  3. Primary melanoma arising 
within a giant congenital melanocytic nevus5.    
Pigment synthesizing melanoma, an uncommon variant, typically present as blue-
black papules and its incidence is skewed toward the first or second decade of life. 6 
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The most common location is the scalp. It is generally known as a low-grade 
malignancy7. It has the tendency to recur locally with satellite nodules and regional 
lymph node spread but distant metastasis is rare. In a review of 190 cases of 
pigment synthesizing melanoma, only 7 (3.7%) were congenital and only 2(1.1%) 
presented with distant metastases. One congenital case was found to have lymph 
node and liver disease multiple months after presentation8.  Due to this rarity, optimal 
treatment is unknown.  Additionally, treatment of metastatic melanoma has 
historically been unsuccessful. Biological basis of neonatal melanoma is unknown. 
They are usually not driven by BRAF. Our tumor had a low frequency MLL3 mutation 
which has been reported in other relapsed/ refractory solid tumors and lymphoma9,10. 
No pathogenic variants were reported in germline sequencing which was reassuring 
and consistent with otherwise negative family history of cancers.  
Nivolumab, a fully human IgG4 human antibody to the PD-1 immune checkpoint, has 
been approved for the treatment of patients with metastatic or unresectable 
melanoma since 2014. By blocking PD-1, nivolumab restores anticancer immune 
responses through abrogation of T cell inhibition mediated through the PD-1 
pathway. A large phase III study in previously untreated adults with metastatic 
melanoma with wild type BRAF demonstrated overall one year survival of 72.9%, 
median progression free survival of 5.1 months and an objective response rate of 
40%11, significant improvements over prior standard of care. Common adverse 
events seen included nausea (16.5%), fatigue (19.9%) and pruritus (17.0%).  
Additionally, checkpoint inhibitors have been associated with autoimmune toxicities 
ranging from colitis to endocrinopathies. In general, the PD-1 inhibitors seem to have 
less severe toxicities, with fewer severe adverse effects and decreased rates of 
discontinuation due to toxicity. This has been postulated to be due to the fact that 
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CTLA-4 inhibitors activate a wider range of T-cell subtypes12. Furthermore, 
autoimmunity secondary to PD-1 inhibition tends to occur later in the treatment 
course (at a median of 59-64 days) and is more likely to involve thyroid dysfunction 
rather than colitis or hypophysitis13,14. We have conducted regular screening 
assessments for endocrine dysfunction, as well as clinical monitoring, and plan to 
continue this throughout her treatment course.  
Only one published study exists looking at checkpoint inhibition in pediatric 
populations15. Toxicities of this treatment were similar to that seen in adults but 
unfortunately, no objective responses were observed. There is no published data on 
checkpoint inhibition in infancy. The efficacy of this approach in infants with 
immature immune systems is unknown. However, data showing cord blood with 
increased expression of the PD-1 molecule on CD4+ T cells in comparison to adult 
peripheral blood upon activation raises the possibility of utility in this population. 
This case demonstrates the safe use of PD-1 checkpoint inhibition in a young infant. 
16.  Our patient initially experienced some early Grade I-II diarrhea and later 
developed Grade II anemia and Grade III neutropenia, none of which required a 
change in therapy. She has continued to grow and develop normally. Following 
initiation of nivolumab, she developed left sided posterior cervical lymphadenopathy. 
Given later improvement, this likely represents pseudo-progression, a phenomenon 
that is seen with the new immunotherapies during which an initial increase in tumor 
size is seen prior to subsequent improvement. On follow-up radiologic and clinical 
evaluations, our patient continues to demonstrate stable disease. Pigment 
synthesizing melanoma tends to be an indolent disease so it is difficult to ascertain 
exactly what contribution the nivolumab has made to her clinical stability. However, 
given lack of significant toxicity, overall tolerability, and stable disease, we plan to 
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continue this treatment. If she develops progressive disease, consideration will be 
given to combination therapy with CTLA-4 inhibition.  
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Figure Legends: 
Figure 1. Initial appearance of the scalp lesion prior to resection 
 
Figure 2. Skin biopsy with atypical spindled and epithelioid heavily pigmented 
melanocytic cells in the dermis (A). Similar atypical melanocytic cells noted in the 
liver (B) and lymph node (C). Few CD8 positive small lymphocytes (arrows) are 
noted adjacent to the melanoma cells (D).  
 
 
